Truist Securities Reiterates Buy on CRISPR Therapeutics, Maintains $220 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has reiterated a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained a price target of $220.
December 08, 2023 | 5:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee reaffirmed a Buy rating on CRISPR Therapeutics and maintained a $220 price target.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst like Joon Lee can instill confidence in investors and potentially lead to a positive short term impact on CRISPR Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100